PYMNTS.com January 19, 2025

23andMe is reportedly considering the sale of Lemonaid Health, its telehealth operation.

The consumer genetic testing kit company acquired Lemonaid in 2021 for $400 million and is now weighing a sale, per a Friday (Jan. 17) Business Insider report that cited sources familiar with the matter.

PYMNTS has contacted 23andMe for comment but has not yet gotten a reply.

The news comes months after 23andMe announced it was cutting more than 200 jobs — or around 40% of its staff — as part of a larger restructuring.

The company’s stock has plunged since a 2023 data breach that exposed the private information of around 7 million customers. 23andMe revealed the breach in October 2023, around six months after it began,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, Mergers & Acquisitions / JV, Technology, Telehealth, Trends
Are third-party telehealth prescriptions of GLP-1s safe?
Unifying telemedicine efforts can help health systems succeed with virtual care
Telehealth For Menopause: Shifting Care Norms And Expanding Access
Communicating with your doctor online could cost you
Iris Telehealth Acquires innovaTel to Expand Telepsychiatry Services

Share This Article